• Brand names:
  • Alyftrek®
• Pharmaceutical Company:
  • VERTEX PHARMACEUTICALS PTY LTD
• Condition/Indication: Cystic fibrosis
• Meeting Date: September 2025
• Public Summary Document (PSD) July 2025 September 2025 PBAC Meetings – (PDF 715 KB)
• Public Summary Document (PSD) July 2025 September 2025 PBAC Meetings – (Word 149 KB)

Related Public Summary Documents

• Vanzacaftor with tezacaftor and with deutivacaftor – July 2025